Project Grant R01FD008174
Award Date
9/15/24
Completion Date
7/31/28
Dollars Obligated
$1.7M
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) aims to advance the treatment and molecular understanding of oculocutaneous albinism (OCA) through gene therapy. The $103,860 award to the University of Pittsburgh will fund research to: Identify the optimal therapeutic window and delivery route for an adeno-associated viral vector gene therapy targeting the TYR gene, which is mutated in OCA1. Evaluate the ability of the TYR gene therapy to rescue...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), is funding the development of OPGX-RHO, a single-vector gene therapy for the treatment of autosomal-dominant retinitis pigmentosa (ADRP). The $882,971 award supports two key objectives: 1) completing chemistry, manufacturing, and controls for a clinical-grade batch of OPGX-RHO, including stability studies and device compatibility testing, and 2) conducting efficacy and...
This Project Grant award of $650,000 from the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103) supports a Phase II expanded access clinical trial of a topotecan chemoplaque treatment for retinoblastoma, a rare childhood eye cancer. The award recipient, Targeted Therapy Technologies, LLC, is developing the topotecan chemoplaque as a single-application therapy to treat refractory retinoblastoma tumors, including solid tumors, vitreous...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) is funding research to develop an innovative gene therapy approach using self-amplifying and self-splicing RNA technologies. The $346,500 award, spanning September 2024 to September 2026, aims to evaluate the longevity, immunogenicity, and potential in vivo side effects of this novel mRNA-based therapy for treating inherited retinal dystrophies. The award recipient, The...
This $1,369,242 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) aims to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) IIIB, a rare lysosomal storage disease. The project focuses on optimizing and scaling up the manufacturing of the AAV9-based gene therapy product containing a codon-optimized human NAGLU cDNA. Phase I activities will involve engineering trials to develop and...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $310,952 to Bedrock Therapeutics, Inc. to develop a novel gene therapy treatment for neovascular age-related macular degeneration (NAMD). The key objectives are to produce the BDRK-501 gene therapy candidate, establish potency assays, and evaluate the efficacy of BDRK-501 in a rat model of NAMD. BDRK-501 combines Bedrock's AAV vector technology and a proprietary HLA-G-based immunomodulatory...
The National Eye Institute (NEI) awarded a $425,000 Project Grant (CFDA 93.867 - Vision Research) to the Massachusetts Eye and Ear Infirmary to conduct large-scale genetic profiling of childhood glaucoma in India. The project aims to identify causal mutations in known childhood glaucoma genes and discover novel genes responsible for this debilitating disease. The research will leverage whole exome sequencing data from 480 childhood glaucoma patients and family members in India to apply quality...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), will fund research to understand the genetic causes of inherited retinal degenerations (IRDs), a group of rare blinding diseases. The $1,369,782 award to the Massachusetts Eye and Ear Infirmary will support two key research aims: Developing a high-throughput splicing assay to identify rare coding and non-coding variants that lead to splicing defects and contribute to the...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $1,241,223 to the University of Pittsburgh to conduct research on the genetic and epigenetic circuits underlying retinal transcription programs and how perturbations in the retinal core regulatory networks lead to congenital vision disorders. The key objectives are to: 1) Use mouse models to dissect the molecular, cellular, and genomic effects of genetic mutations on retinal development; 2)...
The National Institutes of Health's National Eye Institute awarded Greffex Inc. a $902,455 Project Grant under the Vision Research program (CFDA 93.867) to develop an Usher gene therapy. Greffex will leverage its fully deleted adenoviral vector platform, which can accommodate payloads up to 33kb, to deliver a full-length Usher Syndrome Type 2A coding cDNA to photoreceptors. This aims to establish an efficient gene transfer method to treat Usher Syndrome Type 2, the leading genetic cause of...